NDA 019600 · Bausch
Oxsoralen-Ultra
Methoxsalen · Oral
Last checked: Nov 20, 2026Latest source record: Oct 20, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Oct 30, 1986
Approved uses
1
Original approval plus efficacy supplements
Registered trials
40
7 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 30, 1986 Original approval · Type 3 - New Dosage Form
1 products under this application
- OXSORALEN-ULTRA · METHOXSALEN 10MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Methoxsalen" as an intervention, any sponsor and status, largest first.
- A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic CancerPivotal-lookingCompleted
Pancreatic Cancer Action NetworkAcademic, hospital or other
NCT04229004 · 502 participants · Start Jan 31, 2020 · Primary completion Feb 5, 2025
Drug: Gemcitabine combined with nab-paclitaxel; Dose -mFOLFIRINOX and 3 more · For: Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 25 sites in all
- A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic CancerPivotal-lookingTerminated
Tyme, IncIndustry
NCT03512756 · 130 participants · Start Mar 27, 2018 · Primary completion Dec 28, 2021
Drug: SM-88 used with MPS (methoxsalen, phenytoin, sirolimus); Capecitabine, Gemcitabine, and 5-FU · For: Pancreatic Cancer
Sites: Birmingham, Alabama; Duarte, California; Santa Monica, California · 20 sites in all
- PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid ExposurePivotal-lookingNot yet recruiting
Therakos LLCIndustry
NCT07619898 · 112 participants (planned) · Start Jul 2026 · Primary completion Dec 2028
Drug: methoxsalen; Vedolizumab and 3 more · For: Colitis; Hepatitis; Melanoma (Skin Cancer)
- Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis FungoidesPivotal-lookingTerminated
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00056056 · 93 participants · Start Jan 2003 · Primary completion May 2010
Drug: bexarotene; methoxypsoralen · For: Lymphoma
Sites: Graz, Austria; Vienna, Austria; Ghent, Belgium · 28 sites in all
MallinckrodtIndustry
NCT00221000 · 86 participants · Start Aug 2003 · Primary completion Oct 2006
Drug: Methoxsalen · For: Rheumatoid Arthritis
Sites: Westminister, Maryland; Worchester, Massachusetts; Morristown, New Jersey · 32 sites in all
Central Hospital, Nancy, FranceAcademic, hospital or other
NCT03605940 · 78 participants (planned) · Start Oct 1, 2018 · Primary completion Apr 1, 2021
Drug: Corticosteroids · For: Acute-graft-versus-host Disease
Columbia UniversityAcademic, hospital or other
NCT05680558 · 74 participants (planned) · Start May 8, 2021 · Primary completion Mar 2027
Drug: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis · For: Cutaneous T Cell Lymphoma; Mycosis Fungoides
Sites: New York, New York
MallinckrodtIndustry
NCT00054613 · 72 participants · Start Jun 2002
Drug: Methoxsalen · For: Graft-versus-Host Disease
Sites: Little Rock, Arkansas; Gainesville, Florida; Chicago, Illinois · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Photopheresis. Therapeutic potential in preventing restenosis after percutaneous transluminal coronary angioplasty.
Bisaccia E, Palangio M, Gonzalez J, et al. · Am J Cardiovasc Drugs 2003 · Clinical Trial, Controlled Clinical Trial
- Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis.
Lim W, Moon S, Lee NR, et al. · Sci Rep 2024 · Meta-Analysis, Systematic Review
- Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results.
Edelson R, Berger C, Gasparro F, et al. · N Engl J Med 1987 · Clinical Trial, Research Support, Non-U.S. Gov't
- Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group.
Barr ML, Meiser BM, Eisen HJ, et al. · N Engl J Med 1998 · Clinical Trial, Multicenter Study
- Photochemotherapy of psoriasis using methoxsalen and sunlight. A controlled study.
Parrish JA, White AD, Kingsbury T, et al. · Arch Dermatol 1977 · Clinical Trial, Comparative Study
- A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond.
Noel MS, Kim S, Hartley ML, et al. · Cancer Med 2022 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.